Fibromyalgia is still seen as less than legitimate in the medical world. Fortunately, some researchers believe otherwise and many are working on various approaches in treating the condition. The recent drug which received a fast track status from the FDA is IMC-1. This drug is a type of viral suppression drug that showed promising results in treating fibromyalgia.
The Theory between IMC-1 for Fibromyalgia
As mentioned, IMC-1 is a type of viral suppression drug invented and studied by Innovative Med Concepts (IMC) for the treatment fibromyalgia. The main purpose of the drug is to suppress viruses in the body. The theory behind IMC-1 is that the chronic pain syndrome may be related to herpes virus, which lies dormant in the body tissues. Researchers observed that fibromyalgia exhibit the same symptoms with other diseases linked to herpes. They believed that the dormant herpes virus may play a part in triggering and maintaining the symptoms of fibromyalgia. One of the most common fibro symptoms is widespread chronic pain. Others are sleep problems, overwhelming fatigue and mood problems. Many of fibro patients may also suffer from frequent headaches, IBS and cognitive impairment, famously known as the fibro fog.
Related Studies of IMC-1 for Fibromyalgia
IMC-1 is a combination of anti-viral famciclovir and anti-inflammatory celecoxib. The basis of using the drug as treatment is its potential effectiveness in suppressing the herpes virus. Currently, the drug has already completed Phase 2 trials, a double-blinded and placebo-controlled study done by some experts in the medical field. In the study, 143 fibromyalgia participants were randomly given either IMC-1 or a placebo over a 16-week treatment period. Researchers observed and evaluated the participants during the 16 weeks. At the end of the study, participants who took IMC-1 showed less fibromyalgia pain and lower pain scores. This group also reported less fatigue. In general, participants tolerated the drug well.
This study showed a potential treatment option for pain and symptoms of fibromyalgia. It also suggests that suppressing dormant herpes virus can improve the chronic pain syndrome. This finding may lead to more clues to the root of fibromyalgia. IMC is now coordinating with FDA in order to comply with requirements needed for Phase 3 trial which is targeting to commence end 2017.
Although there are around 5 million fibro patients in America, it was only in the recent decade that the chronic pain syndrome gain awareness. There is no definitive fluid test or scans that can confirm the diagnosis and limited options for treatment. This lack of effective treatment is the reason why FDA has granted the Fast Track designation to IMC-1. This designation further encourages drug development for such disease, which doesn’t have many treatment options.
Treating some of the most common symptoms of fibromyalgia will require the use of certain drugs. Among these are painkillers, antidepressants, Lyrica and many more. Doctors also recommend regular exercise, proper diet and getting enough sleep. However, what most fibro patients need is an even quicker and more effective relief from its debilitating symptoms.